Helping patients means transparency and clarity
Every day, thousands of Americans hear the dreaded “c word” from their doctor. I know the fear and the numbness that sets in with the cancer of a loved one.
What happens next can make the difference between life and death. If there’s a treatment that can help, there’s hope. But for some people, hope is a clinical trial that will ultimately determine whether a new therapy can slow or stop their cancer.
The only thing that’s been consistent for digital health accelerators in the past couple of years is that most of them have been tweaking their model. That’s no less true of the New York Digital Accelerator, which is run by the New York eHealth Collaborative and the Partnership Fund for New York City.
The Gaithersburg research and development arm of AstraZeneca said it would begin filing a new request for Food and Drug Administration approval for its biologics annually starting this year.
The National Institutes of Health plans to consolidate several locations in suburban Maryland into a pair of adjacent buildings in Bethesda after wrapping up a roughly nine-month search for alternatives in Montgomery and Prince George’s counties.
Two Maryland-based companies are racing to get a vaccine for respiratory syncytial virus (RSV) to market–and one just picked up a regulatory boost.
MedImmune, AstraZeneca’s ($AZN) biologics research and development arm, announced on Thursday that the FDA is fast-tracking its RSV vaccine, MEDI8897. It joins Novavax ($NVAX), which received FDA fast-track designation for its candidate in November.
The next CONNECTpreneur event is September 28 at the Hyatt Regency Bethesda. More info at connectpreneur.org
There’s a 40% discount code just for eBiz Alert subscribers: Enter CODE: MOCO when you register at http://connectpreneursept2016.eventbrite.com.
This event’s Fireside guest is Seth Goldman, Founder and TeaEO, Honest Tea.
There will be a terrific VC panel including Moderator: Eric Koefoot, Co-Founder and Managing Partner, Public Relay, CEO and Publisher, US News Ventures, Founder and CEO, Five Star Alliance; AJ Jaghori, CEO Solebrity; Founder HelloLoCo; Beth Johnson, Founder and CEO, RP3 Agency; Jeannette Lee, Founder and CEO, Cyper; Founder and CEO, SYTEL.
GlaxoSmithKline’s experimental vaccine to prevent the intensely painful condition known as shingles remained 90 percent effective in people over age 70 even four years after receiving the injection, according to data published on Wednesday.
California Life Sciences Institute (CLSI) today announced the appointment of Heather Shane to build and lead the CLSI CARB-X accelerator, which will provide non-dilutive funding, business support and subject matter expertise to companies with innovative antibiotic product candidates. The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is the world’s largest public-private partnership focused on tackling one of the greatest modern threats to public health — antibiotic resistance. CARB-X will commit $50 million during the first year, and at least $350 million over five years, toward preclinical research and development with the aim of accelerating antibiotic product development over the next 25 years. CLSI is the non-profit partner of the California Life Sciences Association (CLSA), and supports the foundations of innovation – workforce development, STEM education and entrepreneurship – that have made California home to the world’s most prominent life sciences ecosystem.
Crosstown rivals Novartis ($NVS) and Roche ($RHHBY) will be neck and neck for the No. 1 spot in pharma sales till 2022, with Roche ahead by a nose at the finish line, according to a new market analysis. Along the way, a 6.3% annual growth rate industrywide will take global prescription drug sales past the $1 trillion mark.
Accenture has announced the creation of the Accenture HealthTech Innovation Challenge, which aims to bring together startup firms and prominent life sciences and health companies to address challenges including access, affordability, transparency and security.
